Collegium Pharmaceutical Inc.

25.63+0.0400+0.16%Vol 339.86K1Y Perf 17.01%
Nov 30th, 2023 16:00 DELAYED
BID25.14 ASK26.26
Open25.59 Previous Close25.59
Pre-Market- After-Market25.63
 - -  - -%
Target Price
27.40 
Analyst Rating
Strong Buy 1.50
Potential %
6.91 
Finscreener Ranking
+     37.27
Insiders Trans % 3/6/12 mo.
-/-100/-100 
Value Ranking
+     36.80
Insiders Value % 3/6/12 mo.
-/-100/-100 
Growth Ranking
     27.45
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
51.12 
Earnings Rating
Sell
Market Cap835.82M 
Earnings Date
7th Nov 2023
Alpha0.01 Standard Deviation0.16
Beta0.90 

Today's Price Range

25.4725.99

52W Range

20.8330.22

5 Year PE Ratio Range

-19.4035.40

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
-1.57%
1 Month
17.57%
3 Months
7.96%
6 Months
14.68%
1 Year
17.01%
3 Years
36.47%
5 Years
33.56%
10 Years
-

TickerPriceChg.Chg.%
COLL25.630.04000.16
AAPL189.910.54000.29
GOOG133.91-2.4900-1.83
MSFT378.73-0.1200-0.03
XOM102.740.40000.39
WFC44.590.81001.85
JNJ154.662.55001.68
FB196.640.99000.51
GE121.802.94002.47
JPM156.081.76001.14
Financial StrengthValueIndustryS&P 500US Markets
0.80
1.00
0.75
3.71
-0.30
Leverage Ratio 6.20
ProfitabilityValueIndustryS&P 500US Markets
43.80
-3.50
27.80
-83.50
-5.33
RevenueValueIndustryS&P 500US Markets
334.31M
9.96
-1.69
100.09
Earnings HistoryEstimateReportedSurprise %
Q03 20231.111.219.01
Q02 20231.111.131.80
Q01 20231.201.18-1.67
Q04 20220.880.9811.36
Q03 20221.040.96-7.69
Q02 20221.15-0.04-103.48
Q01 20220.820.42-48.78
Q04 20210.86-0.73-184.88
Earnings Per EndEstimateRevision %Trend
12/2023 QR1.30-3.70Negative
12/2023 FY4.770.85Positive
3/2024 QR1.21-11.03Negative
12/2024 FY5.44-1.98Negative
Next Report Date-
Estimated EPS Next Report1.11
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume339.86K
Shares Outstanding32.61K
Shares Float31.41M
Trades Count5.54K
Dollar Volume8.73M
Avg. Volume316.08K
Avg. Weekly Volume315.41K
Avg. Monthly Volume343.02K
Avg. Quarterly Volume289.81K

Collegium Pharmaceutical Inc. (NASDAQ: COLL) stock closed at 25.63 per share at the end of the most recent trading day (a 0.16% change compared to the prior day closing price) with a volume of 339.86K shares and market capitalization of 835.79M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 234 people. Collegium Pharmaceutical Inc. CEO is Joseph J. Ciaffoni.

The one-year performance of Collegium Pharmaceutical Inc. stock is 17.01%, while year-to-date (YTD) performance is 10.47%. COLL stock has a five-year performance of 33.56%. Its 52-week range is between 20.83 and 30.22, which gives COLL stock a 52-week price range ratio of 51.12%

Collegium Pharmaceutical Inc. currently has a PE ratio of -26.30, a price-to-book (PB) ratio of 4.88, a price-to-sale (PS) ratio of 2.80, a price to cashflow ratio of 10.80, a PEG ratio of -1.32, a ROA of -4.68%, a ROC of -1.24% and a ROE of -20.90%. The company’s profit margin is -5.33%, its EBITDA margin is 27.80%, and its revenue ttm is $334.31 Million , which makes it $9.96 revenue per share.

Of the last four earnings reports from Collegium Pharmaceutical Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $1.11 for the next earnings report. Collegium Pharmaceutical Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Collegium Pharmaceutical Inc. is Strong Buy (1.5), with a target price of $27.4, which is +6.91% compared to the current price. The earnings rating for Collegium Pharmaceutical Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Collegium Pharmaceutical Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Collegium Pharmaceutical Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 11.53, ATR14 : 0.72, CCI20 : 63.86, Chaikin Money Flow : -0.09, MACD : 0.88, Money Flow Index : 71.97, ROC : 4.70, RSI : 66.90, STOCH (14,3) : 78.21, STOCH RSI : 0.12, UO : 47.67, Williams %R : -21.79), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Collegium Pharmaceutical Inc. in the last 12-months were: Dreyer Scott (Sold 31 158 shares of value $844 305 ), Joseph Ciaffoni (Option Excercise at a value of $1 397 657), Joseph Ciaffoni (Sold 162 606 shares of value $3 749 892 ), Kuhlmann Shirley (Sold 39 795 shares of value $976 833 ), Kuhlmann Shirley R. (Sold 17 984 shares of value $390 633 ), Michael T. Heffernan (Option Excercise at a value of $4 623 167), Michael T. Heffernan (Sold 298 612 shares of value $6 727 097 ), Scott Dreyer (Sold 17 834 shares of value $488 554 ), Shirley R. Kuhlmann (Sold 21 811 shares of value $586 280 ), Tupper Colleen (Sold 31 640 shares of value $752 083 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (66.67 %)
4 (66.67 %)
4 (66.67 %)
Moderate Buy
1 (16.67 %)
1 (16.67 %)
1 (16.67 %)
Hold
1 (16.67 %)
1 (16.67 %)
1 (16.67 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.50
Strong Buy
1.50
Strong Buy
1.50

Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. It is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing and dissolving. Its product Xtampza ER, is an abuse-deterrent, extended-release, oral formulation of oxycodone.

CEO: Joseph J. Ciaffoni

Telephone: +1 781 713-3699

Address: 100 Technology Center Drive, Stoughton 02072, MA, US

Number of employees: 234

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

55%45%

Bearish Bullish

59%41%

Bearish Bullish

61%39%

 

News

Stocktwits